Adolor Corp., of Exton, Pa., completed enrollment in two Phase II trials of ADL5945 in chronic, noncancer pain patients with opioid-induced constipation. More than 200 patients have enrolled in the placebo-controlled trials that are testing different doses of the µ-opioid receptor antagonist. Adolor expects to report results in the third quarter, with a pivotal trial beginning early next year.